Expertise in
7
conditions

Dr. Benjamin R. Oshrine

Pediatric Hematology Oncology
601 5th St S, 
St Petersburg, FL 
Clinical Trials:Currently Recruiting for 4 Trials
Expertise in
7
conditions
601 5th St S, 
St Petersburg, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Benjamin Oshrine is a Pediatric Hematologist Oncology provider in St Petersburg, Florida. Dr. Oshrine is highly rated in 7 conditions, according to our data. His top areas of expertise are Severe Combined Immunodeficiency (SCID), Graft Versus Host Disease (GvHD), Juvenile Myelomonocytic Leukemia (JMML), Bone Marrow Transplant, and Gastrostomy.

His clinical research consists of co-authoring 40 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

601 5th St S, St Petersburg, FL 33701

Additional Areas of Focus

Dr. Oshrine has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
A Phase II Trial of Reduced Intensity Conditioning and Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplantation for High-risk Solid Tumors
A Phase II Trial of Reduced Intensity Conditioning and Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplantation for High-risk Solid Tumors
Enrollment Status: Recruiting
Publish Date: March 11, 2025
Intervention Type: Drug, Radiation
Study Drugs: Cyclophosphamide, Fludarabine, Melphalan, Tacrolimus
Study Phase: Phase 2
Single-arm, Open-label, Phase 1b/2 Trial of Nivolumab Therapy Following Partially HLA Mismatched (Haploidentical) Bone Marrow Transplant in Children and Young Adults With High Risk, Recurrent or Refractory Sarcomas
Single-arm, Open-label, Phase 1b/2 Trial of Nivolumab Therapy Following Partially HLA Mismatched (Haploidentical) Bone Marrow Transplant in Children and Young Adults With High Risk, Recurrent or Refractory Sarcomas
Enrollment Status: Recruiting
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 1/Phase 2
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 19, 2024
Intervention Type: Biological
Study Phase: Phase 2
The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Procedure, Other, Biological
Study Drugs: Lactobacillus Plantarum Strain 299, Lactobacillus Plantarum Strain 299v
Study Phase: Phase 3
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies
Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drugs: Vorinostat, Azacitidine Injection
Study Phase: Phase 1
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
Enrollment Status: Unknown
Publish Date: November 12, 2020
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
Enrollment Status: Enrolling_by_invitation
Publish Date: November 10, 2020
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Enrollment Status: Completed
Publish Date: August 10, 2020
View 9 Less Clinical Trials

40 Total Publications

Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias.
Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias.
Journal: Blood advances
Published: March 24, 2023
Similar Doctors
Expertise in
15
conditions
Dr. Adrianna Vlachos
Pediatric Hematology Oncology
Expertise in
15
conditions
Dr. Adrianna Vlachos
Pediatric Hematology Oncology
601 5th St S, 
St Petersburg, FL 
 (0.1 miles away)
727-767-3128
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adrianna Vlachos is a Pediatric Hematologist Oncology provider in St Petersburg, Florida. Dr. Vlachos is highly rated in 15 conditions, according to our data. Her top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Aplastic Anemia, and Transient Erythroblastopenia of Childhood.

Expertise in
9
conditions
Dr. Damon R. Reed
Pediatric Hematology Oncology
Expertise in
9
conditions
Dr. Damon R. Reed
Pediatric Hematology Oncology
12902 Usf Magnolia Dr, Fob1 Sarcoma Program, 
Tampa, FL 
 (24.7 miles away)
813-745-3242
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Damon Reed is a Pediatric Hematologist Oncology provider in Tampa, Florida. Dr. Reed is highly rated in 9 conditions, according to our data. His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, and Rhabdomyosarcoma.

Expertise in
14
conditions
Dr. Don E. Eslin
Pediatric Hematology Oncology
Expertise in
14
conditions
Dr. Don E. Eslin
Pediatric Hematology Oncology

Baycare Medical Group, Inc.

3003 W Dr Martin Luther King Jr Blvd, 
Tampa, FL 
 (17.6 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Don Eslin is a Pediatric Hematologist Oncology provider in Tampa, Florida. Dr. Eslin is highly rated in 14 conditions, according to our data. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, Medulloblastoma, Glioma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Oshrine's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 7 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile